New Delhi, Sep 28 (PTI) Drug maker Lupin on Tuesday said it has launched Droxidopa capsules, used in treating orthostatic dizziness, in the US market.

The Mumbai-based company said it has launched the product in the strenghts of 100 mg, 200 mg, and 300 mg, in the US market after having received an approval from the United States Food and Drug Administration (USFDA).

Also Read | Half-Yearly Closing of Bank Accounts 2021: Is It a Bank Holiday on September 30 on October 1? Here's All You Need To Know.

The product is manufactured at the drug maker's Nagpur-based manufacturing plant.

Droxidopa capsules are a generic equivalent of Lundbeck NA's Northera capsules, indicated for the treatment of orthostatic dizziness, lightheadedness, in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure.

Also Read | Rajasthan PTET Result 2021 Declared Today, Candidates Can Check Their Scores Online at ptetraj2021.com.

As per IQVIA MAT July data, Droxidopa capsules had estimated annual sales of USD 294 million in the US. PTI MSS

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)